

Anti-IL-23a Antibody (Risankizumab)

Introduction

Risankizumab (BI 655066) is a humanized IgG monoclonal antibody that targets the IL-23 p19 subunit ($K_d < 10$ pM) and inhibits human IL-23-induced IL-17 production in mouse splenocytes ($IC_{50} = 2$ pM). Risankizumab can be used to study immune and inflammatory diseases such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis.

Product parameters

Alternative Names	SKYRIZI, BI 655066, ABBV-066
Target Accession	Q9NPF7
Target	IL-23a
CAS number	1612838-76-2
Molecular Weight	145.92 kDa
Host	CHO
Reactivity	Human, Cynomolgus
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human IL 23P40 His at 2 ug/mL can bind Anti-IL-23a Antibody (Risankizumab), $EC_{50}=0.04262$ ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μ M filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

■ Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

